Genomic Assay May Predict Long-Term Prognosis in Premenopausal Patients with Hormone Receptor-Positive Early-Stage Breast Cancer; Assay Can Also Help Identify Patients Who May Benefit from Ovarian Suppression Therapy

Ruth O'Regan, MD

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 years of follow-up, according to data presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

Login Or Register To Read Full Story